The biotechnology company Celgene agreed Tuesday to pay $7.2 billion in cash to acquire Receptos, which is developing a potentially promising drug for autoimmune diseases.
Celgene will pay $232 a share, a 12 percent premium to Receptos’s closing price on Tuesday. The deal was announced after markets had closed.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle12
01:02 A company Trump attacked will receive state tax breaks to keep jobs in the U.S12
07:14 Italy Votes in Referendum With PM Matteo Renzi's Future at Stake4
06:21 Carlos Beltran agrees to one-year deal with Houston Astros9